Abstract
Estrogens and insulin/Insulin like growth factor 1 (IGF-I) have potent positive effects on the proliferation of mammary epithelial cells and estrogen-dependent breast cancer cells. A cooperative crosstalk between estrogens and insulin/ IGF-I signaling pathways exists and it plays a critical role in breast carcinogenesis, tumor cell proliferation, differentiation and survival through the modulation of multiple biological events. The biological effects of estrogens are mainly mediated by the activation of estrogen receptor (ERα) whose activity is deeply influenced by the insulin/IGF-I signaling pathway. On the other hand, estrogens enhance insulin signaling by increasing the expression and/or the functional activity of some proteins involved in the insulin/IGF-I pathway. This review will focus on the critical node of the IGF-I network involved in the crosstalk with ERα and implicated in breast cancer development and progression.
Keywords: Estrogen receptor, IGF-I, IGF-IR, Shc, IRS-1, PI3K, Akt, MNAR, ErbB, EGFR
Current Cancer Drug Targets
Title: Interaction Between Estrogen Receptor Alpha and Insulin/IGF Signaling in Breast Cancer
Volume: 8 Issue: 7
Author(s): Marilena Lanzino, Catia Morelli, Cecilia Garofalo, Maria Luisa Panno, Loredana Mauro, Sebastiano Ando and Diego Sisci
Affiliation:
Keywords: Estrogen receptor, IGF-I, IGF-IR, Shc, IRS-1, PI3K, Akt, MNAR, ErbB, EGFR
Abstract: Estrogens and insulin/Insulin like growth factor 1 (IGF-I) have potent positive effects on the proliferation of mammary epithelial cells and estrogen-dependent breast cancer cells. A cooperative crosstalk between estrogens and insulin/ IGF-I signaling pathways exists and it plays a critical role in breast carcinogenesis, tumor cell proliferation, differentiation and survival through the modulation of multiple biological events. The biological effects of estrogens are mainly mediated by the activation of estrogen receptor (ERα) whose activity is deeply influenced by the insulin/IGF-I signaling pathway. On the other hand, estrogens enhance insulin signaling by increasing the expression and/or the functional activity of some proteins involved in the insulin/IGF-I pathway. This review will focus on the critical node of the IGF-I network involved in the crosstalk with ERα and implicated in breast cancer development and progression.
Export Options
About this article
Cite this article as:
Lanzino Marilena, Morelli Catia, Garofalo Cecilia, Panno Luisa Maria, Mauro Loredana, Ando Sebastiano and Sisci Diego, Interaction Between Estrogen Receptor Alpha and Insulin/IGF Signaling in Breast Cancer, Current Cancer Drug Targets 2008; 8 (7) . https://dx.doi.org/10.2174/156800908786241104
DOI https://dx.doi.org/10.2174/156800908786241104 |
Print ISSN 1568-0096 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5576 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
1, 3, 6-Trihydroxy-7-Methyl-9, 10-Anthracenedione Isolated from genus Lindera with Anti-Cancer Activity
Anti-Cancer Agents in Medicinal Chemistry Patent Selections
Recent Patents on Drug Delivery & Formulation Aloperine Induces Apoptosis by a Reactive Oxygen Species Activation Mechanism in Human Ovarian Cancer Cells
Protein & Peptide Letters Benzimidazoles: An Ideal Privileged Drug Scaffold for the Design of Multitargeted Anti-inflammatory Ligands
Mini-Reviews in Medicinal Chemistry Highly Selective MEK Inhibitors
Current Enzyme Inhibition Overexpression of Nemo-like Kinase Promotes the Proliferation and Invasion of Lung Cancer Cells and Indicates Poor Prognosis
Current Cancer Drug Targets TRPV1: On the Road to Pain Relief
Current Molecular Pharmacology In vivo behavior and Safety of Lapatinib-Incorporated Lipid Nanoparticles
Current Pharmaceutical Biotechnology Adjuvant and Neoadjuvant Chemotherapy for Soft Tissue Sarcomas
Current Medicinal Chemistry Use of Analogs of Peptide Hormones Conjugated to Cytotoxic Radicals for Chemotherapy Targeted to Receptors on Tumors
Current Drug Delivery Cancer/Testis Antigens Trigger Epithelial-Mesenchymal Transition and Genesis of Cancer Stem-Like Cells
Current Pharmaceutical Design Natural Naphthoquinones with Great Importance in Medicinal Chemistry
Current Organic Synthesis Nanotherapy Targeting the Tumor Microenvironment
Current Cancer Drug Targets Detecting and Interfering Protein Interactions: Towards the Control of Biochemical Pathways
Current Medicinal Chemistry Epoxyeicosatrienoic Acids as a Therapeutic Target for Nephropathy Associated with Diabetes and Hypertension
Current Hypertension Reviews The Validation Path of Hypoxia PET Imaging: Focus on Brain Tumours
Current Medicinal Chemistry Advances in the Treatment of Ovarian Cancer Using PARP Inhibitors and the Underlying Mechanism of Resistance
Current Drug Targets Modulators of the microRNA Biogenesis Pathway via Arrayed Lentiviral Enabled RNAi Screening for Drug and Biomarker Discovery
Combinatorial Chemistry & High Throughput Screening The Peripheral Benzodiazepine Receptor: A Promising Therapeutic Drug Target
Current Medicinal Chemistry A Progressive Review of V600E-B-RAF-Dependent Melanoma and Drugs Inhibiting It
Mini-Reviews in Medicinal Chemistry